Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 3:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–35 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Hip or Knee (2)

NCT00863304
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 69 more
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis Of The Hip

NCT00744471
Conditions
Arthritis, Osteoarthritis, Osteoarthritis, Hip
Interventions
tanezumab, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
99
States / cities
Mobile, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more
Terminated Phase 3 Interventional Results available

Extension Study Of Tanezumab In Osteoarthritis

NCT00809783
Conditions
Osteoarthritis
Interventions
tanezumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
226
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 148 more
Conditions
Osteoarthritis, Cancer Pain, Recurrent Low Back Pain
Interventions
Investigational medical product (IMP) administered in parent study
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 2 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 1 more
Conditions
Osteoarthritis Pain, Chronic Low Back Pain, Pain Due to Interstitial Cystitis
Interventions
placebo, tanezumab
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Overland Park, Kansas
Conditions
Healthy Volunteers
Interventions
tanezumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cypress, California
Conditions
Osteoarthritis
Interventions
Tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Atlantis, Florida • Fort Myers, Florida • South Miami, Florida + 6 more
Conditions
Osteoarthritis
Interventions
Investigational Medical Product (IMP) administered in parent study
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 36 more
Conditions
Cystitis, Interstitial
Interventions
PF-04383119, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Peoria, Arizona • Fresno, California • Glendora, California + 25 more
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tanezumab for Chronic Low Back Pain

NCT02528253
Conditions
Low Back Pain
Interventions
Placebo to Week 16; tanezumab 5mg SC, Placebo to Week 16, tanezumab 10 mg SC, Tanezumab 5 mg SC, Tanezumab 10 mg SC, Tramadol PR oral
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
179
States / cities
Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 124 more
Conditions
Osteoarthritis, Arthritis
Interventions
NSAID, tanezumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
250
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more